Want to see LPCN full AI Analyst Report?
LPCN Stock Chart & Stats
$2.08
$0.06(2.88%)
At close: 4:00 PM EDT
$2.08
$0.06(2.88%)
Day’s Range― - ―
52-Week Range$1.81 - $12.37
Previous Close$2.1
Volume29.43K
Average Volume (3M)89.50K
Market Cap
$17.23M
Enterprise Value-$2.23
Total Cash (Recent Filing)$23.27M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Nov 11, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding8,244,253
10 Day Avg. Volume42,666
30 Day Avg. Volume89,504
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.02
Price to Sales (P/S)22.14
P/FCF Ratio-4.48
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$6.00Price Target Upside188.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.9
Revenue Forecast (FY)$776.40K
Bulls Say, Bears Say
Bulls Say
Proprietary Oral Delivery & Late‑stage AssetOwning a proprietary oral delivery approach and advancing LPCN 1154 through Phase 3 provides durable strategic optionality: it materially raises the probability of a regulatory path or partner interest, supports differentiation versus IV competitors, and can underpin sustainable market positioning if approved or partnered.
Clean Balance Sheet And Rising CashZero debt and a growing cash balance materially reduce near-term solvency risk and provide runway to advance clinical programs. This financial flexibility supports continued development activities or business development without immediate reliance on dilutive financing, improving resilience over the next several months.
Board And Governance StrengtheningAdding a board member experienced in pharma licensing and M&A plus shareholder approval of incentive expansion signals strengthened governance and a focus on deal‑making. This enhances the company’s ability to monetize assets, secure partnerships, and execute corporate development strategies over time.
Bears Say
Shrinking Revenue And Sizable LossesDeclining top line alongside large, persistent net losses indicates weak commercial traction and poor operational leverage. Over months this compresses resources available for R&D and commercialization, increases dependence on external funding, and undermines the company’s ability to self‑fund pipeline advancement.
Consistent Negative Operating Cash FlowSustained negative operating and free cash flow signals ongoing cash burn that will require financing or partnerships. Even with current cash, continued outflows elevate dilution and execution risk; funding needs could force unfavorable deals or slow development if burn does not abate.
Limited Commercial Scale And ResourcesAn approved product with minimal revenue and a very small team points to constrained commercialization capacity and reliance on partners. This structural limitation reduces odds of scaling sales and diversifying revenue independently, making long‑term growth contingent on successful partnerships or significant investment.
Lipocine News
LPCN FAQ
What was Lipocine’s price range in the past 12 months?
Lipocine lowest stock price was $1.81 and its highest was $12.37 in the past 12 months.
What is Lipocine’s market cap?
Lipocine’s market cap is $17.23M.
When is Lipocine’s upcoming earnings report date?
Lipocine’s upcoming earnings report date is Nov 11, 2026 which is in 80 days.
How were Lipocine’s earnings last quarter?
Lipocine released its earnings results on Aug 04, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.4 by $0.08.
Is Lipocine overvalued?
According to Wall Street analysts Lipocine’s price is currently Undervalued.
Does Lipocine pay dividends?
Lipocine does not currently pay dividends.
What is Lipocine’s EPS estimate?
Lipocine’s EPS estimate is -0.32.
How many shares outstanding does Lipocine have?
Lipocine has 8,244,253 shares outstanding.
What happened to Lipocine’s price movement after its last earnings report?
Lipocine reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.4. Following the earnings report the stock price went up 0.948%.
Which hedge fund is a major shareholder of Lipocine?
Currently, no hedge funds are holding shares in LPCN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lipocine
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
LPCN Stock 12 Month Forecast
Average Price Target
$6.00
▲(188.46% Upside)
Technical Analysis
Ownership Overview
4.61% Insiders
3.10% Mutual Funds
20.74% Other Institutional Investors
68.43% Public Companies and
Individual Investors